Robust sensorimotor deficits in a knock-in mouse model of primary torsion dystonia
Objective: The aim of present study was to (1) generate more powerful tests to detect robust behavioral alterations in the DYT1 knock-in mouse model of…Hospitalisation following different initial therapies in early Parkinson’s disease: Analysis of hospital episodes statistics from the PD MED EARLY trial
Objective: To compare hospitalisation rates of Parkinson's disease (PD) patients randomised between three different classes of oral medications used for early PD treatment. Background: PD…Osmotic demyelination syndrome with dystonia and parkinsonism responsive to dopaminergic therapy
Objective: To present a case of delayed-onset dystonia and parkinsonism secondary to osmotic demyelination syndrome, with dramatic response to pramipexole 3mg per day. Background: Osmotic…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term efficacy results on motor complications from the GLORIA registry
Objective: To evaluate the effect of levodopa-carbidopa intestinal gel (LCIG, designated in the United States as carbidopa-levodopa enteral suspension) on motor fluctuations and dyskinesia in…Priapism and hypersexuality associated with rotigotine in an elderly Parkinsonian patient: A case report
Objective: To describe reversible rotigotine - induced priapism and hypersexuality in a 79-year-old left-handed male with Parkinson's disease (PD). Background: Priapism is a urological emergency…Dopamine agonist withdrawal syndrome (DAWS) in a tertiary Parkinson’s disease center
Objective: To describe the frequency, characteristics and potential risk factors for Dopamine Agonist Withdrawal Syndrome (DAWS). Background: Dopamine agonists are a mainstay of treatment for…AntiParkinsonian effects of AG-0029 in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the motor functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of AG-0029. Background: Parkinson's disease (PD), in which there is widespread degeneration…Randomised trial comparing dopamine agonist, MAOB inhibitor and COMT inhibitor as adjuvant therapy in later Parkinson’s disease (PD)
Objective: The PD MED trial aimed to determine which class of drug provides the best patient-rated quality of life (QoL) when used as adjuvant therapy…Cognitive effects of AG-0029 in the chronic low-dose (CLD) 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaque model of Parkinson’s disease
Objective: To assess the cognitive functions in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated macaques following acute administration of AG-0029. Background: Parkinson's disease (PD), in which there is widespread degeneration…Levodopa-carbidopa intestinal gel in routine care of advanced Parkinson’s disease patients: Final long-term non-motor, quality of life and safety results from the GLORIA registry
Objective: To evaluate the tolerability and effect of levodopa-carbidopa intestinal gel (LCIG, designated in the US as carbidopa-levodopa enteral suspension) on non-motor symptoms (NMS), quality…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.